Find Funding Opportunities

Returning 144 results

Small Research Grant Program for the Next Generation of Researchers in Basic Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)

RFA
Wednesday, April 25, 2018
Wednesday, July 4, 2018
R03
RFA-AG-19-003

Funding Opportunity Purpose

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.

BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)

RFA
Thursday, April 19, 2018
Wednesday, November 11, 2020
R01
RFA-NS-18-030

Funding Opportunity Purpose

This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Saturday, May 8, 2021
R61/R33
PAR-18-763

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Saturday, May 8, 2021
R61/R33
PAR-18-762

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Saturday, May 8, 2021
R61/R33
PAR-18-761

Funding Opportunity Purpose

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.

Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)

PAR
Tuesday, April 3, 2018
Saturday, September 1, 2018
PAR-18-740

Funding Opportunity Purpose

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program

Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)

PAR
Friday, March 30, 2018
Sunday, September 8, 2019
R03
PAR-18-733

Funding Opportunity Purpose

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 - Clinical Trial Not Allowed)

PAR
Friday, March 30, 2018
Sunday, September 8, 2019
R03
PAR-18-734

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)

PAR
Wednesday, March 28, 2018
Wednesday, May 27, 2020
R21
PAR-18-721

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental translational research (R21). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)

PAR
Thursday, March 15, 2018
Wednesday, May 8, 2019
K22
PAR-18-711

Funding Opportunity Purpose

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

Pages